Biogen (BIIB) Cash from Operations Growth (1y) (2010 - 2026)
Biogen (BIIB) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
220.11% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-39.77% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
134.19% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
- |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
56.72% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
57.37% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
44.79% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
11.99% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
148.94% |
| Date | Value |
|---|
| Mar 31, 2026 |
148.94% |
| Dec 31, 2025 |
-32.72% |
| Sep 30, 2025 |
36.01% |
| Jun 30, 2025 |
-74.29% |
| Mar 31, 2025 |
-53.13% |
| Dec 31, 2024 |
5,987.20% |
| Sep 30, 2024 |
57.93% |
| Jun 30, 2024 |
28.50% |
| Mar 31, 2024 |
21.50% |
| Dec 31, 2023 |
107.14% |
| Sep 30, 2023 |
-10.38% |
| Jun 30, 2023 |
-33.88% |
| Mar 31, 2023 |
181.40% |
| Dec 31, 2022 |
-120.88% |
| Sep 30, 2022 |
-17.92% |
| Jun 30, 2022 |
-39.99% |
| Mar 31, 2022 |
-78.96% |
| Dec 31, 2021 |
328.36% |
| Sep 30, 2021 |
-31.82% |
| Jun 30, 2021 |
-37.01% |
